167 related articles for article (PubMed ID: 33396968)
61. In vitro Study on Synergistic Interactions Between Free and Encapsulated Q-Griffithsin and Antiretrovirals Against HIV-1 Infection.
Minooei F; Fried JR; Fuqua JL; Palmer KE; Steinbach-Rankins JM
Int J Nanomedicine; 2021; 16():1189-1206. PubMed ID: 33623382
[TBL] [Abstract][Full Text] [Related]
62. Naturally Occurring Mutations to Muscle-Type Creatine Kinase Impact Its Canonical and Pharmacological Activities in a Substrate-Dependent Manner In Vitro.
Mosher EP; Eberhard CD; Bumpus NN
Mol Pharmacol; 2021 Dec; 100(6):588-596. PubMed ID: 34561299
[TBL] [Abstract][Full Text] [Related]
63. Development of pH-sensitive vaginal films based on methacrylate copolymers for topical HIV-1 pre-exposure prophylaxis.
Notario-Pérez F; Galante J; Martín-Illana A; Cazorla-Luna R; Sarmento B; Ruiz-Caro R; das Neves J; Veiga MD
Acta Biomater; 2021 Feb; 121():316-327. PubMed ID: 33333257
[TBL] [Abstract][Full Text] [Related]
64. Development of tenofovir monobenzyl ester phosphonoamidate prodrugs with improved anti-hepatitis B virus activity and intrahepatic tenofovir enrichment.
Sun X; Song L; Lin L; Ding A; Wang C; Ma X; Zhou S; Cai J; Tang H
Bioorg Med Chem; 2024 Feb; 99():117607. PubMed ID: 38246114
[TBL] [Abstract][Full Text] [Related]
65. Discovery of Modified Amidate (ProTide) Prodrugs of Tenofovir with Enhanced Antiviral Properties.
Kalčic F; Zgarbová M; Hodek J; Chalupský K; Dračínský M; Dvořáková A; Strmeň T; Šebestík J; Baszczyňski O; Weber J; Mertlíková-Kaiserová H; Janeba Z
J Med Chem; 2021 Nov; 64(22):16425-16449. PubMed ID: 34713696
[TBL] [Abstract][Full Text] [Related]
66. Stimuli-sensitive thiolated hyaluronic acid based nanofibers: synthesis, preclinical safety and in vitro anti-HIV activity.
Agrahari V; Meng J; Ezoulin MJ; Youm I; Dim DC; Molteni A; Hung WT; Christenson LK; Youan BC
Nanomedicine (Lond); 2016 Nov; 11(22):2935-2958. PubMed ID: 27785967
[TBL] [Abstract][Full Text] [Related]
67. Tenofovir-tethered gold nanoparticles as a novel multifunctional long-acting anti-HIV therapy to overcome deficient drug delivery-: an in vivo proof of concept.
Fotooh Abadi L; Kumar P; Paknikar K; Gajbhiye V; Kulkarni S
J Nanobiotechnology; 2023 Jan; 21(1):19. PubMed ID: 36658575
[TBL] [Abstract][Full Text] [Related]
68. Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis.
Flexner C; Thomas DL; Swindells S
Curr Opin HIV AIDS; 2019 Jan; 14(1):13-20. PubMed ID: 30394948
[TBL] [Abstract][Full Text] [Related]
69. Antiviral supramolecular polymeric hydrogels by self-assembly of tenofovir-bearing peptide amphiphiles.
Monroe MK; Wang H; Anderson CF; Qin M; Thio CL; Flexner C; Cui H
Biomater Sci; 2023 Jan; 11(2):489-498. PubMed ID: 36449365
[TBL] [Abstract][Full Text] [Related]
70. ω-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties.
Pribut N; D'Erasmo M; Dasari M; Giesler KE; Iskandar S; Sharma SK; Bartsch PW; Raghuram A; Bushnev A; Hwang SS; Burton SL; Derdeyn CA; Basson AE; Liotta DC; Miller EJ
J Med Chem; 2021 Sep; 64(17):12917-12937. PubMed ID: 34459598
[TBL] [Abstract][Full Text] [Related]
71. Effect of drug-to-lipid ratio on nanodisc-based tenofovir drug delivery to the brain for HIV-1 infection.
Garcia CR; Rad AT; Saeedinejad F; Manojkumar A; Roy D; Rodrigo H; Chew SA; Rahman Z; Nieh MP; Roy U
Nanomedicine (Lond); 2022 Jun; 17(13):959-978. PubMed ID: 35642549
[No Abstract] [Full Text] [Related]
72. Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.
Owen A; Rannard S
Adv Drug Deliv Rev; 2016 Aug; 103():144-156. PubMed ID: 26916628
[TBL] [Abstract][Full Text] [Related]
73. Poly(ethylene glycol)-
Cagnon ME; Curia S; Serindoux J; Cros JM; Ng F; Lopez-Noriega A
Pharmaceutics; 2021 Apr; 13(5):. PubMed ID: 33922166
[TBL] [Abstract][Full Text] [Related]
74. Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis.
Ilomuanya MO; Hameedat AT; Akang EN; Ekama SO; Silva BO; Akanmu AS
Futur J Pharm Sci; 2020; 6(1):81. PubMed ID: 33241057
[TBL] [Abstract][Full Text] [Related]
75. Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations.
Hobson JJ; Curley P; Savage AC; Al-Khouja A; Siccardi M; Flexner C; Meyers CF; Owen A; Rannard SP
Nanoscale Adv; 2019 Nov; 1(11):4301-4307. PubMed ID: 36134394
[TBL] [Abstract][Full Text] [Related]
76. Lactoferrin nanoparticles coencapsulated with curcumin and tenofovir improve vaginal defense against HIV-1 infection.
Yeruva SL; Kumar P; Deepa S; Kondapi AK
Nanomedicine (Lond); 2021 Mar; 16(7):569-586. PubMed ID: 33660529
[No Abstract] [Full Text] [Related]
77. Current drugs for HIV-1: from challenges to potential in HIV/AIDS.
Peng Y; Zong Y; Wang D; Chen J; Chen ZS; Peng F; Liu Z
Front Pharmacol; 2023; 14():1294966. PubMed ID: 37954841
[TBL] [Abstract][Full Text] [Related]
78. A review of existing strategies for designing long-acting parenteral formulations: Focus on underlying mechanisms, and future perspectives.
Shi Y; Lu A; Wang X; Belhadj Z; Wang J; Zhang Q
Acta Pharm Sin B; 2021 Aug; 11(8):2396-2415. PubMed ID: 34522592
[TBL] [Abstract][Full Text] [Related]
79. Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects.
Wan L; Zhang X; Gunaseelan S; Pooyan S; Debrah O; Leibowitz MJ; Rabson AB; Stein S; Sinko PJ
AIDS Res Ther; 2006 Apr; 3():12. PubMed ID: 16635263
[TBL] [Abstract][Full Text] [Related]
80. [New reality in HIV therapy: Long-acting, injectable drugs].
Oldenbuettel C; Wolf E
MMW Fortschr Med; 2022 Jun; 164(Suppl 2):44-51. PubMed ID: 35731489
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
